CANTARGIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.45 SEK | -0.58% |
|
-7.46% | -7.70% |
| Sales 2024 * | - | Sales 2025 * | 578M 52.79M 4.22B | Capitalization | 634M 57.93M 4.64B |
|---|---|---|---|---|---|
| Net income 2024 * | -280M -25.59M -2.05B | Net income 2025 * | -96M -8.78M -702M | EV / Sales 2024 * | - |
| Net Debt 2024 * | 56.6M 5.17M 414M | Net Debt 2025 * | 657M 60.04M 4.8B | EV / Sales 2025 * | 2.23 x |
| P/E ratio 2024 * |
-1.6
x | P/E ratio 2025 * |
-1.84
x | Employees | 22 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cantargia AB
More press releases
| 1 day | -0.58% | ||
| 1 week | -7.46% | ||
| Current month | -1.15% | ||
| 1 month | +18.15% | ||
| 3 months | -4.70% | ||
| 6 months | -7.51% | ||
| Current year | -7.70% |
1 week
3.32
3.83
1 month
3.104.80
Current year
2.564.80
1 year
2.566.15
3 years
2.5635.78
5 years
2.5671.80
10 years
2.5671.80
| Managers | Title | Age | Since |
|---|---|---|---|
Göran Forsberg
CEO | Chief Executive Officer | 61 | 08/07/14 |
Patrik Renblad
DFI | Director of Finance/CFO | 54 | 14/06/23 |
David Liberg
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Magnus Nilsson
BRD | Director/Board Member | 68 | 25/05/21 |
| Chairman | 64 | 31/12/15 | |
Damian Marron
BRD | Director/Board Member | 62 | 25/05/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.45 | -0.58% | 264,059 |
| 25/04/24 | 3.47 | -2.80% | 331,410 |
| 24/04/24 | 3.57 | -3.51% | 285,166 |
| 23/04/24 | 3.7 | -0.80% | 380,337 |
| 22/04/24 | 3.73 | +0.05% | 478,715 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotes
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Calendar
21/05/2024
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.45
SEK
Average target price
12.67
SEK
Spread / Average Target
+267.15%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.70% | 57.8M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CANTA Stock
